6533b82bfe1ef96bd128cdb0

RESEARCH PRODUCT

Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial

Lucía Márquez-mosqueraCarlos TaxoneraLuísa CastroMaria EsteveXavier CalvetCristina AlbaD CeballosPilar Martínez-montielJoaquín HinojosaVicente Vega RuizAna EcharriVicente PonsEva IglesiasIsabel Vera-mendozaMiguel MinguezAntonio López-sanrománIgnacio Marín-jiménezJavier P. GisbertPilar NosJordi RimolaJordi GuardiolaFernando BermejoE. DomènechJesús BarrioMaría Dolores Martín-arranz

subject

AdultMaleQuality of lifemedicine.medical_specialtyPostoperative therapyAzathioprinePostoperative recurrence03 medical and health sciences0302 clinical medicineCrohn DiseaseQuality of lifeRecurrenceSurveys and QuestionnairesInternal medicineAzathioprineAdalimumabHumansMedicineIn patientPostoperative PeriodCrohn's diseaseHepatologybusiness.industryRemission InductionGastroenterologyAdalimumabSpanish versionProphylactic drug therapymedicine.diseaseEndoscopes GastrointestinalCrohn's diseaseSpain030220 oncology & carcinogenesisQuality of LifeFemale030211 gastroenterology & hepatologyIntestinal resectionbusinessImmunosuppressive Agentsmedicine.drug

description

Background: In APPRECIA trial, Crohn's disease (CD) patients undergoing intestinal resection were randomized to postoperative adalimumab (ADA) or azathioprine (AZA). Aims: To evaluate health-related quality of life (HRQoL) in APPRECIA trial. Methods: HRQoL was evaluated using disease-specific shortened Spanish version of the IBDQ (SIBDQ-9) and generic European Quality of Life-5 Dimensions (EQ-5D) questionnaires, completed at baseline and at weeks 24 and 52. Results: Sixty-one patients (37 ADA and 24 AZA) had evaluable data for HRQoL. Patients treated with ADA or AZA had significant improvement from baseline to weeks 24 and 52 in SIBDQ-9 and EQ-5D (p < 0.001 and p = 0.006 for all comparisons, respectively). There were no differences between treatment arms in mean change in SIBDQ-9 and EQ-5D at weeks 24 and 52 vs baseline. Only patients without endoscopic recurrence had significant improvement in SIBDQ-9 (p < 0.001) and EQ-5D (p < 0.001) at week 52. At week 52, there was a high to moderate negative correlation between CDAI score with SIBDQ-9 score( Pearson's r: -0.768) and with EQ-5D index (r: -0.644). Conclusion: HRQoL improved after intestinal resection in CD, irrespective of the postoperative therapyused (ADA or AZA). Outcomes in HRQoL were associated with prevention of endoscopic recurrence, sinceimprovements in HRQoL were only significant in patients with endoscopic remission at 1 year. (c) 2019 Editrice Gastroenterologica Italiana S. r. l. Published by Elsevier Ltd. All rights reserved.

yearjournalcountryeditionlanguage
2019-01-01
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4296